{"id":8764,"date":"2024-04-22T11:07:18","date_gmt":"2024-04-22T09:07:18","guid":{"rendered":"http:\/\/www.neurochirurgie-lariboisiere.com\/meningioma-research\/"},"modified":"2025-09-23T21:44:35","modified_gmt":"2025-09-23T19:44:35","slug":"meningioma-research","status":"publish","type":"page","link":"https:\/\/www.neurochirurgie-lariboisiere.com\/en\/elementor-17917\/research\/meningioma-research\/","title":{"rendered":"Meningiomas and progestins"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Research activities of the Neurosurgery Department <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The department has a particular interest in studying the links between meningiomas and exogenous sex hormones.<\/p>

Our team was the first to demonstrate a causal link between meningiomas and cyproterone acetate (ANDROCUR*), as well as links with other progestins such as normegestrol acetate (LUTENYL*) and Chlormadinone acetate (LUTERAN*).<\/p>

> To clarify the relationship between drug intake, and in particular the dose and duration of treatment, and the development of meningiomas, a study was carried out by the French Assurance Maladie in cooperation with the neurosurgery department at Lariboisi\u00e8re Hospital.<\/a>

This study was carried out on 250,000 women exposed to cyproterone, comparing those who received high doses (more than 3g over 6 months, i.e. at least 3 boxes, then continued treatment) with those who received low doses (less than 3g over 6 months, i.e. one or two boxes, then stopped treatment). The occurrence of meningioma in these women was therefore monitored for 7 years.<\/p>

The results indicate that exposure to high-dose cyproterone acetate exposes women to a 7-fold increased risk of meningioma managed in Neurosurgery, compared with the group of low-exposure women who stopped treatment.<\/p>

There is also a strong relationship between dose and effect, with the risk increasing more than 20-fold above a cumulative dose of 60 g, i.e. around 5 years’ treatment at 50 mg\/d or 10 years’ treatment at 25 mg\/d (when taken 20 days a month).<\/p>

Read more : <\/strong><\/h4>

\"\"<\/a>Androcur (cyproterone acetate) and generics <\/a><\/h3>

Risk of meningioma with prolonged use – Information point<\/h3>

<\/p>

\"\"<\/a>Lutenyl*<\/a> \/ <\/a>Luteran* <\/a> <\/h3>

Risk of meningioma with prolonged use<\/h3>

\"\"AMAVEA Association <\/a><\/h3>

Association Cyproterone acetate meningiomas <\/strong><\/p>

References:<\/h3>